Recognized one-time severance and restructuring costs in Q1 2026 following the divestiture of the semiconductor business.

On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline ...

Highlights for the Quarter ended March 31, 2026Management and advisory fee revenue of $18.3 million for the quarter ended March 31, 2026, a decrease of 3.7% from the first quarter of 2025.Incentive fe ...

Pixelworks, Inc. (NASDAQ: PXLW) ("Pixelworks" or the "Company"), a provider of innovative cinematic and enhanced visualization ...

Strong first quarter results with revenue of $357.9 million- Life Sciences: MediBeacon receives the CE mark for the Transdermal ...

"As previewed on the previous conference call in February, Q1 was a transformational quarter for Pixelworks." (President, CEO & Chairman Todd DeBonis) "After closing the sale of our Shanghai-based ...

Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson’s Disease; TFL data from the SAD study arm targeted for first half of 2027 - – Closed $21.2 million private placement ...

National Healthcare Properties, Inc. (Nasdaq: NHP) (the 'Company”), a self-managed real estate investment trust focused on ...

3 Stocks That Could Be Next to Announce a Stock Split McKesson (NYSE:MCK) reported a stronger fiscal fourth quarter and full ...

McKesson’s latest earnings call struck a confident tone, with management highlighting broad-based growth, expanding margins and strong cash generation across fiscal 2026. While they acknowledged ...